Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Thiosemicarbazone-based Molecular Hybrids as Prototypes for Antitumor Drugs: Recent Advances in the Last Decade.

Created on 12 Nov 2026

Authors

Caio Victor S Soares, João Pedro P Gomes, Antonio Miguelsinho M DE Sousa Filho, Luiz Vitor O Lima, Cidla S Marinho, Ana Karoline R Novais, Maria DO Carmo A DE Lima, Jamerson F DE Oliveira

Published in

Anais da Academia Brasileira de Ciencias. Volume 98. Issue 4. Pages e20260029. Epub Nov 09, 2026.

Abstract

Molecular hybridization is used in the development of drug prototypes through the combination of bioactive compounds, being useful in the development of new drugs with antitumor action, given the high complexity of the disease. Thiosemicarbazones are interesting structures for the development of hybrids, enabling the discovery of unexplored mechanisms of action and new alternatives in cancer treatment. In this study, we report data on new thiosemicarbazone hybrids from the last 10 years (2015-2025), identifying the main bioactive groups, pharmacological targets, and cell lines of interest. The study indicates a strong trend towards hybridization with nitrogenous heterocycles (52%), with emphasis on indole, quinoline, and pyridine groups. Regarding targets, VEGFR-2 (Vascular Endothelial Growth Factor Receptor 2) and different topoisomerases are particularly prominent. The main cell lines used in cytotoxicity studies were MCF-7 (36 studies), MDA-MB-231 (21 articles), A549 (21 articles), and HepG-2 (20 articles). Only 20 compounds showed IC50 values below 2 µM, with emphasis on those hybridized with nitrogenous groups. Thus, thiosemicarbazone hybrids, especially those conjugated with nitrogenous compounds, show promise for exploration in the development of antitumor prototypes.

PMID:
43018008
Bibliographic data and abstract were imported from PubMed on 12 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 8
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement